Anomalies in Pfizer Options Trading Data: Two Strategies to Consider

The Pfizer (PFE) options market has recently shown extraordinary movements that warrant traders’ attention. A $29 put expiring on March 20 generated a volume/open interest (Vol/OI) ratio of 210.16—so high that it exceeds the activity of the next most traded Alphabet (GOOG) put by 35%. Such anomalies in trading data require in-depth analysis to understand the market’s true intentions behind this options activity.

Pfizer presents a fascinating case study. Once a symbol of the global healthcare boom, the stock has experienced a significant contraction: from around $61.71 in 2021, shares have fallen to the $20 area, a 59% decline. For outsiders observing the market, identifying a convincing reason to take a bullish position seems complex. However, the unusual options trading volume suggests that someone sees interesting opportunities at current price levels.

When Pfizer Options Volume Breaks the Norm

What caught attention was particularly notable in raw numbers. The $29 put expiring March 20 saw 30,263 contracts traded versus an open interest of just 144—highlighting a massive, concentrated bet. With a market cap of $144 billion, Pfizer remains a top-tier company, yet typical options trading on this stock does not usually show this level of concentration.

Looking at historical patterns, Pfizer’s 30-day average options volume is about 142,695 contracts. Recent activity reached 1.39 times this average, marking the busiest day since December 17. Compared to the quarterly peak of 890,898 contracts after the Q3 2025 earnings announcement on November 4—when options volume hit 376,442 contracts in that session—the movement remains significant but not at all-time highs.

These developments trace back to December 16, when Pfizer reaffirmed its 2025 outlook and provided modest guidance for 2026, projecting a median adjusted EPS of $2.90, down from $3.08 in 2025. This announcement triggered a two-day price decline, after which the stock mostly oscillated between $25 and $25.50. It’s in this relatively uncertain context that unusual options activity emerged.

Long Straddle: Betting on Implied Volatility

One of the most notable options strategies on Pfizer involves a long straddle. This setup occurs when an investor buys both the $29 put and the $29 call with the same March 20 expiration. The strategy aims to profit from large price moves regardless of direction: the trader benefits if the stock moves significantly above or below $29.

The net cost of this long straddle is $4.38 per share (or $438 per contract). This cost sets the breakeven points at $33.38 upward and $24.62 downward. With Pfizer trading around $25.43, the stock is relatively close to the lower breakeven.

What makes this setup interesting is the associated probability: roughly 37% chance that the long straddle will be profitable at expiration. While not extremely high in absolute terms, the advantage lies in timing: 71 days until expiration (DTE). Professional traders typically prefer a window of 30-45 days, as it offers enough time for significant moves without excessive time decay. In this case, 71 days presents a reasonable waiting period.

A fascinating aspect of options trading emerges when comparing a long straddle to a simple long call. With an expected move of 6.96%, the stock could reach $27.05 downward—well below the call’s breakeven at $31.58, rendering that call out of the money. Conversely, a $1.76 downward move would bring the price to $23.53, just 3.6% below the long straddle’s breakeven at $24.62. In this scenario, profit would be about $89. Annualized, such a limited move could generate a return of 128%, a remarkable performance over a 71-day horizon.

Bull Put Spread: More Conservative Bullish Strategy

The second notable options setup on Pfizer is the bull put spread—a fundamentally bullish strategy that assumes the stock will rise or at least stay above critical levels. It involves selling the $29 put for a premium of $390 and buying a $26 put as protection for $156. The net credit received is $234.

The maximum potential loss is limited to $66, calculated as the difference between strikes ($3) times 100, minus the premium received. This yields a risk-reward ratio of about 0.28 to 1, meaning for every $100 of potential gain, only $28 is at risk. If the stock closes above $29 at expiration, the full profit of $234 is realized—equivalent to a 354.55% return over the period, which annualizes to about 1,848.73%.

While the probability of success (stock above $29) is roughly 33%, the breakeven point is at $26.66, about 4.84% above the current price. Given the expected market move of 6.96%, there’s a profit zone between $26.66 and $29. This price range makes the bull put spread attractive for traders seeking a lower-risk profile compared to a long straddle.

Which Trading Strategy to Choose?

Comparing these two options strategies reveals significant differences in risk profile and market outlook. The long straddle works best when high volatility is expected but the direction is uncertain—ideal for capital protection while betting on surprise moves. The bull put spread suits traders with a moderate bullish view and lower risk tolerance.

In Pfizer’s case, the choice between these strategies depends on individual outlook and risk appetite. For those seeking exposure with limited risk and believing in a rebound, the bull put spread is the more straightforward approach. For traders aiming to capitalize on uncertainty and benefit from significant moves in either direction, the long straddle offers a compensating alternative. In both cases, the unusual volume in options trading suggests the market is pricing in a major event—and savvy traders should pay close attention.